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ABSTRACT 
Our genetic makeup is composed of thousands of genes that code for the proteins involved in 
all aspects of cellular function. Proteins are molecular machines that dynamically and 
structurally respond to stimuli. Cells are able to sense their environment and react accordingly 
through the help of receptors – a type of protein – embedded in the cellular membrane that 
binds extracellular molecules known as ligands. The innate ability of receptors to specifically 
interact with and influence structural changes in partner proteins forms the basis for signalling 
cascades that regulate cellular processes. In diseased individuals, genetic mutations can result 
in changes in the structure of proteins that will affect the tertiary and quaternary structures of a 
protein or proteins in complex. This can have drastic effects on protein function – ultimately 
compromising cellular fate.  
The use of animal and plant-based products in modern medicine led to the development of 
pharmacology – the study of drug effects in living organisms. Receptor-labelling techniques 
and molecular cloning enabled us to establish that many of these molecules were acting on a 
family of proteins called G protein-coupled receptors (GPCRs). Our knowledge of the 
structural changes exerted on the receptor upon ligand binding has led to the development of 
new drugs with increased subtype specificity and fewer side effects.  
While our knowledge related to prototypical GPCRs like adrenoreceptors and opioid receptors 
has flourished in recent years, their distantly related cousins – known as Frizzleds (FZDs) and 
Smoothened (SMO) – have suffered from an inability to assess their GPCR nature. FZDs 
interact with the WNT family of lipoglycoproteins and SMO is indirectly regulated by 
Hedgehog (Hh) to orchestrate important processes in embryonic development and adult 
homeostasis. Misregulation of WNT and Hh signalling leads to the pathogenesis of numerous 
diseases for which treatments are limited. With respect to WNT signalling, the lack of effective 
drugs targeting FZDs is in large part due to a knowledge gap resulting from current dogma that 
places emphasis on protein complex formation rather than the structural changes involved in 
protein activation.  
The findings compiled in papers I to III provide structural insight into the mechanisms 
underlying FZD/SMO activation. A combination of genomic, biophysical and biochemical 
approaches was used to unravel the details surrounding FZD/SMO complex formation and the 
structural dynamics upon ligand binding that lead to full receptor activation and downstream 
signalling. This has implications for the development of effective treatments for diseases where 
FZDs and SMO can be targeted. Characterizing the conformational landscape of these 
receptors will enable us to drive drug discovery efforts forward.  
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1 INTRODUCTION 
More than 100 years ago, the first sex-linked mutation was discovered in Drosophila 
melanogaster that would serve as the basis for a flurry of genetic studies based on phenotypic 
screening (Morgan, 1910). More than half a century later, efforts to dissect the genes involved 
in segment polarity converged on wingless flies and short larvae with spiky cuticles (Sharma 
and Chopra, 1976; Wieschaus et al., 1984). These phenotypes were found to be the result of 
misregulation in the WNT and Hedgehog (Hh) pathways respectively – signalling pathways 
that direct embryonic development and are involved in pathophysiology. 
1.1 WNT SIGNALLING 
The gene product that would later be identified as WNT was originally discovered through a 
hypomorphic mutation in the wg1 allele (Sharma and Chopra, 1976). Studies on the mouse 
mammary tumor virus (MMTV) revealed the insertion/integration of proviral DNA into a gene 
that was appropriately called int-1 (Nusse and Varmus, 1982). However, it was later shown 
that wg and int-1 were identical leading to the current nomenclature for the gene family – WNT 
(wingless-related integration site) (Nusse et al., 1991; Rijsewijk et al., 1987). Analysis of the 
gene product and further biochemical validation revealed that WNTs were secreted proteins. 
The finding that WNT was a morphogen involved in cell-to-cell communication led to the 
hypothesis that there must be a transmembrane receptor transducing these signals. Cells 
expressing Dfz2 were able to bind Wg suggesting that Frizzled proteins were the receptors for 
WNT molecules (Bhanot et al., 1996). In Drosophila, there are seven WNT and four FZD genes 
(Wu and Nusse, 2002). In mammals, this number is scaled up to 19 WNT and 10 FZD genes 
(Schulte, 2010). The specificity of these interactions has yet to be completely elucidated 
especially given the fact that redundancy exists among WNT-FZD pairs and the inherent 
difficulties in assessing interactions between full-length FZD and purified WNT – not to 
mention the potential involvement of co-receptors (Dijksterhuis et al., 2015; Eubelen et al., 
2018; Wu and Nusse, 2002). 
The overlap in phenotypes linked to segment polarity in Drosophila and the inability to 
decipher the linearity of signalling pathways and the gene products involved therein provoked 
the use of biochemical assays to identify the composition of functional protein complexes.   
1.1.1 WNT/β-catenin signalling 
Armadillo – the Drosophila equivalent of the intracellular signal transducer -catenin – was 
found to accumulate in regions where Wg/WNT was expressed in the developing fly embryo 
(Riggleman et al., 1990). In line with this observation, embryos harbouring mutations in 
armadillo were found to have the same defect in segmentation of the body plan as wg, 
porcupine and dishevelled (DVL) (Clevers, 2006; Theisen et al., 1994). Later, it was discovered 
that a single-pass transmembrane protein called arrow in Drosophila or low-density 
lipoprotein-receptor-related protein (LRP) in vertebrates formed a complex with Frizzled 
proteins to transduce Wg signals across the membrane (Wehrli et al., 2000). With the 
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identification of mutations in the Drosophila gene shaggy/zeste-white 3 – known as glycogen 
synthase kinase 3 (GSK3) in vertebrates – a regulatory component was implicated in segment 
polarity (Peifer et al., 1994). Soon thereafter, the mutants that shared similar phenotypes were 
found to constitute a new signalling pathway – the WNT/-catenin pathway.  
This pathway has been reviewed extensively by others (Clevers, 2006; Grainger and Willert, 
2018; Nusse and Clevers, 2017; Steinhart and Angers, 2018) and will only briefly be described 
here. It should be noted, however, that specific WNTs (e.g. WNT-1 and WNT-3A) and FZDs 
(e.g. FZD4 and FZD5) display a higher propensity to initiate this signalling cascade.  In the 
absence of WNT, -catenin is part of the cytosolic “destruction complex” with Axin, 
adenomatous polyposis coli (APC), GSK3 and CK1. Axin acts as a scaffold to facilitate 
phosphorylation of -catenin by GSK3 and CK1. Phosphorylated -catenin is then 
ubiquitinated by E3 ubiquitin ligases and targeted for proteasomal degradation. When WNT 
binds FZD/LRP, a signalosome is thought to form, allowing for FZD-bound DVL and LRP to 
become phosphorylated. Phosphorylation of LRP is carried out by GSK3 and CK1 leading to 
the recruitment of Axin from the “destruction complex.” This promotes the stabilization of -
catenin and its translocation to the nucleus where it acts as a transcriptional co-activator with 
the transcription factors T cell factor/ lymphoid enhancer factor (TCF/LEF).  
To date, slightly over half of the 19 WNTs are available for purchase as recombinant protein 
albeit with unknown specific activity and antibodies with sufficient isoform selectivity do not 
exist to be able to detect and distinguish heterologous expression in cells. This has hampered 
efforts to exhaustively characterize which WNTs are activating the -catenin pathway. An 
added level of complexity comes from the finding that other proteins at the interface of 
WNT/FZD signalling may be required for certain WNT paralogues to achieve signal 
specification (Eubelen et al., 2018). However, WNTs are not the only ligands that bind to FZDs 
and initiate -catenin signalling. Investigation into retinal vascularization led to the discovery 
of a molecular oddity. The similarity in vascular phenotypes exhibited by patients with either 
Norrie disease or familial exudative vitreoretinopathy (FEVR) suggested that the respective 
disease-associated variants, Norrin and FZD4 respectively, were a ligand-receptor pair (Xu et 
al., 2004). Moreover, the signalling outcome of Norrin binding to FZD4 was found to be 
activation of the -catenin pathway. The diversity in ligand-FZD pairs, not only within the 
WNT family of lipoglycoproteins, but extending to other secreted proteins of unique protein 
structures reiterates the notion that there remains a large knowledge gap in our understanding 
of how FZDs or FZD-containing complexes transduce extracellular signals. 
1.1.2 -catenin-independent signalling 
Classification of the different WNT signalling branches was originally based on studies in 
Drosophila, Xenopus and zebrafish of which two -catenin-independent pathways were 
proposed: WNT/planar cell polarity (PCP) and WNT/Ca2+ (Niehrs, 2012). The number of 
components found to participate in these pathways has grown substantially in recent years. In 
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general, pathway selectivity is thought to be dependent on specific co-receptors, WNTs and 
higher order complex formation.  
In the case of PCP, asymmetry is established through molecular complexing on adjacent cells. 
Briefly, FZD forms complexes with cadherin EGF LAG seven-pass G-type receptor (CELSR) 
and WNT co-receptors like receptor tyrosine kinase-like orphan receptor (ROR) or receptor 
tyrosine kinase (RYK). CELSR forms homotypic interactions in cis associating with FZD-
DVL in one cell and Van Gogh-like protein (VANGL)-Prickle in the other (Chen et al., 2008). 
This intercellular complex can be destabilized through the dissociation of Prickle from 
VANGL (Ressurreição et al., 2018). Surface expressed and stabilized FZD binds WNT 
mediating the activation of the small GTPase Ras homolog gene family, member A (RhoA) – 
a process that requires DVL interaction with Dishevelled-associated activator of 
morphogenesis (DAAM) (Habas et al., 2001). The differential expression of these higher order 
complexes on opposing cells results in asymmetric cell division and cell fate determination.   
The production of second messengers in the case of receptor ligands that cannot cross the 
plasma membrane triggers the activation of kinases that amplify signalling cascades. The 
production of cAMP or the mobilization of intracellular calcium are two second messenger 
systems that are intrinsically linked to GPCRs. Expression of WNT and FZD in zebrafish 
embryos led to the release of intracellular calcium which was blocked by inhibitors of inositol 
monophosphatase and pertussis toxin-sensitive G proteins (Slusarski et al., 1997). Because the 
release of Ca2+ is known to activate protein kinase C (PKC), follow-up studies tested whether 
WNT or FZD paralogues or the synergistic combination of both could lead to the recruitment 
of PKC to the plasma membrane and its subsequent activation. Not all WNTs or FZDs were 
capable of stimulating PKC reinforcing the idea that different signalling pathways existed 
downstream of specific WNT-FZD pairs (Sheldahl et al., 1999). During that period, it was 
well-known that DVL was involved in both WNT/-catenin and WNT/PCP pathways albeit 
through different mechanisms – the Dishevelled-Axin (DIX) domain of DVL being required 
for the former, but not the latter. In a mechanism that was found to be both WNT- and G 
protein-independent, it was found that DVL was also able to mediate calcium mobilization in 
like manner to WNT/PCP signalling (Sheldahl et al., 2003). Although initially thought to be a 
distinct signalling pathway from WNT/PCP, WNT/Ca2+ has also been shown to regulate 
convergent extension suggesting that some overlap may exist between the two pathways.  
There is a certain reluctance to designate the common denominator of WNT signalling. Even 
in the case of the WNT/-catenin pathway, there is evidence for the involvement of G proteins 
(Katanaev et al., 2005; Liu et al., 2001). As for the -catenin-independent signalling branches, 
the downstream proteins or second messengers that have been implicated therein have direct 
or indirect links to heterotrimeric G proteins. Although there is strong evidence for the 
involvement of DVL in all three branches of WNT signalling, it is not clear whether DVL 
facilitates G protein-mediated signalling or forms its own ternary complex with WNT and FZD 
to drive signal transduction.  
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1.2 HEDGEHOG SIGNALLING 
Mutations in the genes encoding either Hh and Smoothened (SMO) resulted in a naked cuticle 
phenotype in Drosophila (Nüsslein-Volhard et al., 1984; Wieschaus et al., 1984). Around that 
time, it was thought that the cellular response to WNTs depended on the activity of Patched 
(PTCH) (Hidalgo and Ingham, 1990). PTCH is another protein involved in segment polarity 
that antagonizes Hh signals (Ingham et al., 1991). For a while, the interplay between these 
signalling molecules was not understood and it was thought that SMO might also be a receptor 
for Hh (Alcedo et al., 1996). Later studies revealed that PTCH was the receptor for Hh (three 
paralogues in vertebrates) and the molecular basis for this interaction was recently elucidated 
by cryo-EM (Gong et al., 2018; Qi et al., 2018). Like the WNT/β-catenin pathway, Hh 
signalling has been reviewed at length elsewhere (Arensdorf et al., 2016; Schulte, 2010). In 
short, when Hh is absent, PTCH represses SMO preventing glioma-associated oncogene (Gli) 
proteins from translocating to the nucleus to regulate gene transcription. Hh binds to PTCH 
relieving its inhibition of SMO. SMO is thought to be constitutively active and signal to Gli 
through unknown intracellular mediators to induce target gene expression. The mechanism 
through which PTCH controls SMO activity is still an area of active research. One hypothesis 
is that PTCH is a sterol transporter that regulates the availability of cholesterol for SMO – 
thought to act as an endogenous ligand for SMO activation (Gong et al., 2018; Taipale et al., 
2002).  
The mystery surrounding the endogenous ligand has also been an area of intense research and 
debate. Studies involving heterozygous PTCH+/- mice demonstrated an increased likelihood to 
develop medulloblastoma. Microarray analysis revealed an enrichment of transcripts involved 
in sterol synthesis. Further experimentation demonstrated that cholesterol and oxysterols could 
regulate SMO activity (Corcoran and Scott, 2006). Despite belonging to Class F, SMO does 
not bind WNTs (Wu and Nusse, 2002). Much like FZD4, SMO has had a different evolutionary 
trajectory that is both similar and different to FZDs resulting in interaction with different 
ligands and/or higher constitutive activity. An interesting parallel between FZD and SMO 
ligands is the fact that WNTs are lipidated. It is attractive to assume that members of the Class 
F evolved to recognize nonpolar ligands via the CRD groove. However, this is clearly not the 
case for the FZD4 ligand Norrin which is not lipidated and is predicted to engage two FZD4 
protomers simultaneously through an alternative CRD interface and molecular contacts with 
the linker domain (Bang et al., 2018; Shen et al., 2015). Another line of research suggests that 
while cholesterol and oxysterols may serve as ligands for SMO, it is not clear if they are 
allosteric modulators or true orthosteric agonists. In other words, it is not clear where the 
primary binding site of the endogenous SMO ligand is located. Non polar molecules like 
cholesterol have been shown to modulate the activity of other GPCRs in an allosteric manner 
much like ions (Dawaliby et al., 2016; Guixà-González et al., 2017).  
The molecular intermediates that connect SMO activation to Gli in vertebrates are still a matter 
of debate. Based on the 7TM structure of SMO, heterotrimeric G proteins became a reasonable 
candidate. However, the physiological link between SMO and G proteins in vivo is 
controversial. Nevertheless, several studies have shown that SMO can functionally activate 
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heterotrimeric G proteins (Myers et al., 2017; Ogden et al., 2008; Riobo et al., 2006). Accepting 
SMO as a GPCR has been hindered by the translational aspect of these findings due to 
indications that pertussis toxin – an exotoxin inhibitor of Gi – does not entirely prevent Hh 
signalling in different model organisms (Arensdorf et al., 2016; Philipp and Caron, 2009). This 
rationale fails to consider the possibility that SMO is capable of interacting with other 
heterotrimeric G proteins that are pertussis toxin-insensitive or that SMO can form ternary 
complexes with intracellular transducers other than G proteins to mediate Gli activation.  
1.3 G PROTEIN-COUPLED RECEPTORS 
The quest to understand how pharmacological agents work began at the turn of the 19th century 
with the Nobel Prize-winning work of Paul Ehrlich who famously stated in Latin, “corpora 
non agunt nisi fixata” or “a substance does not work unless it is bound” (Ehrlich, 1913). This 
was long before we knew that FZDs and SMO were receptors or that they belonged to the G 
protein-coupled receptor (GPCR) superfamily. It would take years before studies aimed at 
understanding the link between the enzyme adenylyl cyclase and hormones would ultimately 
bring this to fruition. Adenylyl cyclase catalyses the breakdown of ATP into the second 
messenger cAMP and pyrophosphate. Hormonal activation of adenylyl cyclase depends on the 
presence of GTP (Rodbell et al., 1971). Purification of this unknown regulatory component led 
to the identification of the first G protein (Northup et al., 1980). Meanwhile, chromatography 
experiments revealed that the G protein interacted with the -adrenergic receptor in the 
presence of receptor agonist, but not antagonist (Limbird et al., 1980). Another piece of the 
puzzle was provided by the topographic model of the photoreceptor rhodopsin (Hargrave et al., 
1984) – illustrating the conserved architecture consisting of seven hydrophobic helices that 
would become the foundation for the classification of proteins belonging to the GPCR 
superfamily.  
1.3.1 Class F receptors  
After the cloning of the gene for the -adrenergic receptor (Dixon et al., 1986) and with the 
advent of human genome sequencing years later (Venter et al., 2001), we learned that there 
were more than 800 GPCR genes that were subsequently grouped into six classes based on 
phylogenetic analysis: Class A (rhodopsin-like), Class B (secretin receptor family), Class C 
(metabotropic glutamate), Class D (fungal mating pheromone receptors), Class E (cAMP 
receptors) and Class F (frizzled/smoothened) (Alexander et al., 2017). Consistent with other 
members of the GPCR superfamily, Class F receptors have the traditional 7TM architecture 
consisting of seven transmembrane-spanning -helices connected by three extracellular (ECL) 
and intracellular loops (ICL) (Fig. 1). In mammals, there are eleven members: FZD1-10 and 
SMO. However, despite homologous topology, Class F receptors displayed a very different 
evolutionary history that was highly conserved across model organisms including worms, flies, 
sea quirts, fish and mammals in contrast to all other GPCR subfamilies (Schiöth and 
Fredriksson, 2005). 
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Structural differences in the GPCR superfamily begin to 
appear at the amino- and carboxy-terminal extremities. 
In contrast to Class A receptors, Class F receptors have 
an extracellular domain (ECD) similar to the receptors 
of Class B called a cysteine-rich domain (CRD). CRDs 
are also found in Class C receptors, secreted frizzled-
related proteins (sFRPs) (Rattner et al., 1997) and 
several receptor tyrosine kinases (Masiakowski and 
Carroll, 1992) (the latter two of which are involved in 
WNT signalling). However, the ECD of Class C 
receptors is unusually large due to the adjacent Venus 
flytrap domain that serves as the orthosteric ligand 
binding site and is involved in receptor dimerization 
mediated by intermolecular disulfide bonds. Whereas 
the orthosteric binding site in Class A/B/C GPCRs is 
well-defined, further work is needed to understand the 
binding mode of the endogenous ligands for Class F 
receptors. In particular, our knowledge of the orthosteric 
binding site on FZDs comes from a crystal structure of 
recombinant CRD in complex with WNT (Janda et al., 
2012). While this may be true, in vivo evidence suggests 
that the CRD is dispensable for WNT binding (Chen et 
al., 2004a; Lisovsky et al., 2002) – suggesting that there 
is more to the story. Moreover, methodological 
limitations have prevented the characterization of WNT 
affinity for full-length FZD. In Class B and F GPCRs, a 
linker connects the ECD to the transmembrane core and 
is presumed to play a role in the binding mode of the ligand either through orientation of the 
ECD relative to the core or contributions to the accessible surface area (Bang et al., 2018; Siu 
et al., 2013; Valnohova et al., 2018). On the opposite side of the membrane, the cytosolic tail 
of GPCRs varies in length – even within the Class F – and it is not clear to what degree the 
polypeptide sequence is helical or disordered. That being said, the C-terminal PSD95/Dlg1/zo-
1 (PDZ) binding motif that is known to regulate GPCR signalling and trafficking is found 
among members of the Class F (Schulte, 2010). In particular, this domain mediates interactions 
with the scaffolding protein DVL via residues on all intracellular loops and the KTxxxW motif 
that precedes the PDZ binding motif – the latter being present in all FZDs, but not SMO. 
Interestingly, the parathyroid hormone receptor (PTHR – Class B) has a similar stretch of 
amino acids (KSxxxW) that also allows for interaction with DVL (Romero et al., 2010). 
One of the major arguments against FZDs behaving as GPCRs has been the lack of conserved 
motifs with Class A receptors in the 7TM region (Angers and Moon, 2009). FZDs lack the 
DRY and NPxxY motifs that are proposed to be involved in receptor activation and G protein 
Fig. 1. Space-filling model of Class F 
receptor bound to WNT. Xenopus 
WNT-8 (red) (PDB ID: 4F0A) has been 
overlain with human SMO (PDB ID: 
5V57). The CRD of SMO is depicted in 
yellow, the linker domain in green and 
7TM domain in grey. The crystal 
structure of SMO was used for illustrative 
purposes to show how a WNT molecule 
bound to the CRD would appear relative 
to the core of a Class F receptor. 
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coupling. Furthermore, Class F 
receptors do not possess the 
prototypical switches that regulate 
receptor activity; in particular, none of 
the 11 paralogues have an ionic lock 
between TM3 and TM6. Class C 
GPCRs have an ionic lock (Doré et al., 
2014) whereas Class B GPCRs do not 
(Hollenstein et al., 2013). Recent 
structural data from FZD4 and 
homology models based on SMO 
point to the existence of a traditional 
GPCR-like binding pocket 
(orthosteric in Class A/B; allosteric in 
Class C) in the transmembrane 
domain – the accessibility of which 
has been brought into question (Yang 
et al., 2018).  
In short, the differences and 
similarities between Class F (Fig. 2) 
and the rest of the GPCR superfamily underline the evolutionary trajectories that allowed for 
adaptation to different ligands in different cellular/tissue contexts that converge on related 
intracellular transducers yielding different responses of varying amplitudes and kinetics.  
1.3.2 Ternary complex model and GEF activity 
The observation that agonist/hormone (H) affinity for the receptor (R) was sensitive to 
nucleotides led to the postulation of a ternary complex model whereby the G protein (X) 
stabilizes the complex in the absence of enzymatic activity where K, L, K′ and M are constants 
(De Lean et al., 1980; Limbird et al., 1980). In other words, an agonist will have a higher 
affinity for the receptor when functionally interacting with the G protein (Fig. 3). This 
observation is reinforced on a structural level where a lid-like structure encapsulates the 
receptor-bound ligand when the receptor is functionally engaging the intracellular transducer 
(Devree et al., 2016). These findings were extended to other 7TM receptors as well as other 
intracellular effectors – both physiological and surrogate-based. Physiological ternary 
complexes for which the affinity shift of an agonist-bound receptor has been observed include 
heterotrimeric G protein, arrestin (Gurevich et al., 1997) and G protein-coupled receptor kinase 
(GRK) (Komolov et al., 2017) (Fig. 4). G protein surrogates in the form of nanobodies or 
engineered G protein can also induce the affinity shift characteristic of a high affinity complex 
and have provided structural insight into ternary complex formation where sufficient 
stabilization of protein structure has been problematic (Manglik et al., 2017; Shimada et al., 
2018). Findings that GPCRs can preassociate with G proteins in the absence of ligand and that 
Fig. 2. Phylogenetic tree of human FZD and SMO 
paralogues. Maximum-likelihood phylogenetic tree depicting 
the homology clusters of all Class F members. 
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allosteric modulators can affect agonist affinity led to 
the development of the cubic ternary complex and the 
quaternary complex model respectively 
(Christopoulos and Kenakin, 2002; Weiss et al., 1996) 
– the inclusion of more variables will inevitably lead to 
more complicated models.   
Heterotrimeric G proteins are composed of three 
subunits: Gα , Gβ and Gγ.  In particular, the Gα  subunit 
acts as a weak GTPase in the absence of regulators of 
G protein signalling (RGS) by catalyzing the 
hydrolysis of GTP (active) to GDP (inactive) and 
consists of two domains that are involved in nucleotide 
binding: the Ras domain and the α -helical domain. 
Like GPCRs, Gα  subunits are divided into different 
families: Gα s, Gα i/o, Gαq/11, Gα12/13 (Milligan and 
Kostenis, 2006). It is well-established that GPCRs 
exhibit a degree of G protein specificity and that some 
GPCRs can interact with more than one subfamily of G protein through selectivity determinants 
(Flock et al., 2017). This selectivity is achieved through contacts between the receptor and the 
Ras domain of the Gα  subunit. The α -helical domain of the Gα  subunit is flexible allowing for  
exchange of GDP for GTP (Rasmussen et al., 2011a). The exchange of GDP for GTP is 
facilitated by the guanine nucleotide exchange factor (GEF) activity of the GPCR. The outward 
movement of TM6 on the receptor exposes a larger surface area for the α5 helix of the Ras 
Fig. 3. Ternary complex model. 
Observations that an agonist had different 
affinities for its receptor depending on the 
presence or absence of intracellular 
transducer led to the development of the 
ternary complex model. – Adapted from De 
Lean et al., 1980 and illustrated by Jennifer 
M. Wright 
Fig. 4. Ternary receptor complexes. The term GPCR has become a misnomer due to the ability of other 
intracellular effector proteins to bind the receptor and allosterically affect agonist affinity. Heterotrimeric G 
proteins, arrestins and GRKs can all form ternary complexes. With respect to Class F receptors, the question 
arises whether other proteins like DVL for FZDs or Cos2 for SMO in Drosophila can also form ternary 
complexes. – Adapted from Schulte and Wright, 2018 
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domain to become fully engaged with the cytoplasmic cavity of the 7TM bundle (Carpenter 
and Tate, 2017). This results in the opening of the nucleotide binding site and subsequent 
displacement of GDP. The nucleotide-free state of the G protein is short-lived due to the 
relatively high levels of GTP present in the cell. Then, either the heterotrimer undergoes a 
structural rearrangement or G dissociates from G where they can act as effectors elsewhere 
in the cell (Bunemann et al., 2003; Digby et al., 2006; Galés et al., 2006). Previously, the life 
cycle of a GPCR was thought to be complete after dissociation of the heterotrimeric G protein 
from the agonist-bound receptor, which leads to phosphorylation by GRKs and receptor 
desensitization by arrestins. However, it is now understood that GRKs bind to the agonist-
bound receptor – albeit with a weaker affinity than the heterotrimeric G protein – to form an 
alternative ternary complex. Phosphorylation of the receptor by GRK leads to the recruitment 
of arrestin which results in receptor internalization and rheostat-like signalling that is 
modulatory of G protein signalling (Grundmann et al., 2018; Irannejad et al., 2013; Luttrell et 
al., 2018).  
In the context of FZDs, selected paralogues have been found to assemble with heterotrimeric 
G proteins in an inactive state (although the presence of endogenous WNTs could be a 
confounding factor) and DVL, which can interact with FZD in a ligand-independent manner 
(Arthofer et al., 2016; Hot et al., 2017; Kilander et al., 2014; Valnohova et al., 2018). It has 
also been shown that LRP5/6 can directly bind to FZD (Ren et al., 2015) – a finding that 
requires further investigation to determine how this interaction affects WNT-FZD-transducer 
cooperativity. 
1.3.3 Oligomerization  
Dating back to the 1970s, bindings curves that revealed differences in cooperativity were 
proposed to support the existence of higher order complexes with more than one binding site 
(Bouvier, 2001). Findings from co-immunoprecipitation experiments and immunoblotting 
have provided evidence for dimers/higher order oligomers (Fig. 5A). This approach was used 
to demonstrate that Xenopus FZD3 dimerizes whereas FZD7 does not. It was further shown that 
by artificially constraining FZD7 to form dimers, the WNT/-catenin pathway could be 
activated (Carron et al., 2003). However, receptor solubilization can induce artefacts due to the 
hydrophobic nature of GPCRs and domain swapping does not provide information about the 
native protein function. In order to circumvent this, there was a push in assay development to 
probe for the presence of dimers in living cells. Bioluminescence resonance energy transfer 
(BRET) is a process that occurs naturally in the sea pansy, Renilla reniformis. Degradation of 
coelenterazine by luciferase results in luminescence that can be transferred to green fluorescent 
protein (GFP) when the two proteins are in proximity to one another (<100 Å). Through 
molecular cloning, luciferase and red-shifted GFP can be fused to proteins of interest. In the 
present context, two populations of receptors can be tagged with donor and acceptor molecules 
enabling the assessment of dimers in living cells (Angers et al., 2000) (Fig. 5B). BRET assays 
suggested that FZD1,2,4 dimerize via their heptahelical domain and that this process is important 
in receptor trafficking (Kaykas et al., 2004). However, the inability to distinguish random 
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Fig. 5. Methods to detect dimerization. Over the last decades, methods have developed or been adapted 
to increase sensitivity, account for stoichiometry and quantitatively assess oligomerization. (A) 
Immunoblotting has been used to probe for dimers based on their relative size with the help of antibodies 
in co-immunoprecipitation experiments or crosslinkers of varying lengths and chemical reactivity.  (B) 
BRET is performed in living cells and provides an indication of the relative distance between proteins based 
on energy transfer from luciferase-tagged proteins to red-shifted GFP-tagged proteins. In order to 
convincingly show that RET is dependent on stoichiometry and not just acceptor density, different amounts 
of donor DNA should be transfected. Typically, the expression of acceptor should exceed expression of the 
donor. (C
protein populations when one population represented by a particular colour (in this case green) can be 
immobilized by antibody or crosslinker. The two colours (protein populations) are bleached and the 
recovery of the mobile protein population (red) is monitored for differences in its lateral mobility before 
and after immobilization of the green population. (D) FCCS tracks the movement of fluorescently-tagged 
molecules through a detector volume over time. If two proteins are interacting or co-diffusing then a cross-
correlation amplitude will be observed. (E) Single-molecule tracking of proteins labelled with cell-
impermeable fluorescent dyes has been used to acquire information about the size of particles over varying 
receptor densities and co-diffusion of molecules. – Illustration by Jennifer M. Wright 
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collisions from stable interactions and problems in estimating stoichiometry with BRET led to 
the use of saturation curves that have become the subject of debate and controversy in the field 
of GPCR dimerization (Lan et al., 2015) (see 3.3 Affinity vs. proximity and the role of 
stoichiometry). Another approach known as dual color fluorescence recovery after 
photobleaching (dcFRAP) made use of fluorescent receptors where one receptor population 
could be immobilized by antibodies or crosslinkers in order to test whether the other receptor 
population would be slowed in its lateral mobility (Digby et al., 2006; Dorsch et al., 2009) (Fig. 
5C). Problems inherent to receptor overexpression and the need for receptor crosslinking led 
to the use of assays capable of tracking single molecules over time. Fluorescence correlation 
spectroscopy (FCS) has single molecule sensitivity and can measure fluorescence fluctuations 
within a defined detector volume providing information about movement, concentration and 
aggregation (Fig. 5D). When protein populations labelled with two colours are expressed in 
living cells, their movement can be correlated to determine whether the proteins are in complex 
or not. However, this method is technically difficult to carry out, suffers from photobleaching 
if red-shifted fluorescent protein chimeras are used and does not rule out the presence of other 
protein intermediates that allow for correlated movement (Briddon et al., 2018). With the help 
of algorithms, another technique with single molecule resolution made use of total internal 
reflection fluorescence microscopy (TIRF-M) to study receptor organization in living cells 
(Fig. 5E). These studies highlighted the dynamic nature of receptor-receptor interactions that 
were highly variable in their sensitivity to ligand addition (Calebiro et al., 2013). In spite of 
these findings, the functional relevance of dimers was still an open question. The discovery 
that purified GPCRs could be embedded into high-density lipoprotein (HDL) particles as 
monomers provided strong evidence for the ability of a monomer to activate G proteins in the 
presence of receptor agonist. Furthermore, the authors proposed that the difference in 
cooperativity was due to G protein binding and not dimerization (Whorton et al., 2007). While 
the aforementioned study yielded direct support to the ternary complex model (De Lean et al., 
1980), it does not preclude the existence of dimers or the potential that they may have some 
effect on G protein activation. For example, members of the Class C form covalent dimers via 
their ligand-binding domain and this has functional consequences for receptor activation (Xue 
et al., 2015). To sum up, the difficulties in measuring stoichiometry, defining oligomeric 
interfaces and excluding protein intermediates have slowed down our pharmacological 
understanding of the relevance of GPCR dimers, which necessitates further studies.  
1.4 CLASS F PHARMACOLOGY AND CONFORMATIONAL BIAS 
A great deal of confusion revolves around the pharmacology of Class F receptors. Instead of 
finding common ground on a structural level given their sequence homology, the peculiarities 
of SMO compared to other Class F members has driven research efforts in opposing directions.  
SMO was long thought to be a constitutively active orphan receptor, activated indirectly by Hh 
and repressed through an unknown mechanism by PTCH. A curious observation that ingestion 
of a particular plant species by pregnant sheep could induce cyclopia in fetal lambs was 
ultimately shown to involve the binding of a teratogen called cyclopamine to the 7TM bundle 
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of SMO (Chen et al., 2002; Keeler and Binns, 1966). Given the importance of oncogenic SMO 
in cancer, the finding that the receptor core could be modulated by small molecules provided a 
logical starting point for drug development. In fact, while drug development for SMO has 
focused on its GPCR architecture, there is still a debate as to whether it functions in a 
physiological context as a GPCR (Arensdorf et al., 2016). The first structure of a Class F 
member was that of human SMO bound to the antitumour agent LY2940680 (Wang et al., 
2013). In contrast to FZDs, less focus has been placed on the role of the CRD in SMO activity 
– especially in the design of small molecule drugs – although oxysterols have been found to 
bind the hydrophobic groove in the CRD and play a role in pathway activation (Byrne et al., 
2016). Nevertheless, the rearrangements observed in the binding pocket of agonist- and 
antagonist-bound SMO structures do not support the differences observed in receptor activity 
(e.g. SMO-induced Gli transcriptional regulation) (Zhang et al., 2018). Furthermore, the 
identity of the endogenous SMO ligand is still controversial with some indications that it could 
be cholesterol or oxysterols (Byrne et al., 2016; Huang et al., 2016; Luchetti et al., 2016; Myers 
et al., 2013). This problem is complicated by the fact that the endogenous regulator of SMO 
activity, Hh, binds PTCH and not SMO. The question arises whether SMO has evolved a 
constitutive activity that is agonist-independent in vivo, but repressed in a graded fashion by 
PTCH under normal circumstances. To date, SMO has not been crystallized with any 
intracellular transducer. Therefore, we can only speculate about conformational bias and the 
development of biased ligands. SMO has been shown to interact directly with Costal-2 (Cos2) 
in Drosophila; however, human SMO does not bind Cos2 (De Rivoyre et al., 2006). In addition, 
G protein-coupled receptor kinase 2 (GRK2), protein kinase A (PKA) and casein kinase 1 
(CK1) are known to phosphorylate SMO, but the mechanism through which Hh stimulation 
and PTCH inactivation allows these kinases to activate SMO is unknown (Chen et al., 2004b; 
Zhao et al., 2007). However, there is an abundance of literature that demonstrates the ability of 
SMO to couple to and activate heterotrimeric G proteins (Arensdorf et al., 2017; Myers et al., 
2017; Riobo et al., 2006). Both agonists and inverse agonists that target the 7TM bundle of 
SMO are known to affect G protein activation. For this reason, it would be interesting to 
uncover the conformational changes and structural motifs involved in receptor activation and 
GEF activity. Moreover, an understanding of how SMO is conformationally repressed by 
PTCH would be of enormous value as this remains a big question mark in the field of Hh 
signalling. The concept of pathway selectivity does not appear to apply to SMO – at least not 
in the same way that it does to WNT/FZD signalling (see below). However, phosphorylation 
of SMO leads to the recruitment of -arrestin – a process that can be inhibited by small 
molecule inverse agonist (Chen et al., 2004b). As for other GPCRs, one could think of 
developing biased SMO ligands for the purpose of targeting specific intracellular transducers 
that are activated by SMO (Hauser et al., 2017).  
With regard to FZDs, emphasis has been placed on the CRD in large part due to the WNT-
CRD structure and the inexistence of a ligand-bound 7TM structure. This has led to the 
development of CRD-targeting antagonists – some of which have proceeded to clinical trials. 
Unfortunately, insufficient paralogue selectivity has resulted in serious issues in 
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polypharmacology (Schulte and Wright, 2018). Moreover, it is not clear in view of the full-
length receptor whether WNT binding to FZD results in a reorientation of the CRD relative to 
the core resulting in a secondary binding site that contacts residues elsewhere on the receptor 
to mediate receptor activation. This information is especially important given the evidence that 
the CRD does not appear to be required for WNT signal transduction through FZD (Chen et 
al., 2004a). Without a better understanding of the binding mode of WNT proteins, we cannot 
pinpoint the location of the orthosteric site on full-length FZD. This problem has been 
compounded by an endemic nomenclature problem in the WNT field that treats proteins and 
drugs that negatively affect WNT/-catenin signalling as antagonists. A pharmacological 
overhaul is needed to recharacterize current treatment modalities and to characterize new ones 
– all of which requires more structural data (Neubig et al., 2003). As mentioned before, 
understanding pathway selectivity and bias is far more complex in WNT signalling. 
Endogenous allosteric modulators of FZDs in the form of co-receptors [e.g. LRP5/6, ROR1/2, 
RYK, Tyrosine-protein kinase-like 7 (PTK7)] or dimers could affect cooperativity of ligand 
binding according to the allosteric ternary complex model, dictate specificity among the 19 
WNTs and influence pathway selectivity (Christopoulos and Kenakin, 2002; Eubelen et al., 
2018; Liang et al., 2018a; May et al., 2007). The first structure of the 7TM domain of FZD – 
that of FZD4 – revealed a hydrophilic pocket like SMO that was claimed to be unfavourable 
for ligand binding (Yang et al., 2018). Interestingly, the first crystal structure of SMO in 
complex with LY2940680 made similar claims about the size and hydrophilicity of the pocket 
(Wang et al., 2013). The fact that the FZD4 structure is in the apo state – the first such 7TM 
structure – suggests that the narrow binding pocket could be partially collapsed. It is attractive 
to speculate that FZDs evolved Class F-specific conformational switches that take part in GEF 
activity and dynamic kinks in TM7 that mediate interaction with other binding partners like 
DVL (Yang et al., 2018). Further studies into the conformational changes that guide pathway 
selectivity will drive drug discovery efforts forward.  
1.5 SIGNALLING KINETICS AND SIGNAL AMPLIFICATION IN WNT/HH 
SIGNALLING 
The long held belief that the response induced by a drug is proportional to the number of 
occupied receptors was brought into question after it was shown that the histamine receptor 
antagonist phenoxybenzamine was resistant to washout, but stimulation of unbound receptor 
reserve with histamine could still elicit a maximum response until all receptors were occupied 
by antagonist (Nickerson, 1956). As mentioned previously, the receptor-mediated GEF activity 
is sufficiently rapid such that one receptor can activate many G proteins – one molecule of 
rhodopsin can activate as many as 1000 molecules of transducin during one 
activation/deactivation cycle (Vuong et al., 1984). The potential of the receptor to amplify the 
signal through the subsequent activation of many effector molecules implies that lower 
concentrations of agonist can result in full activation of downstream responses (Ross, 1989). 
These observations were instrumental in developing concepts of spare receptors/receptor 
reserve and signal amplification. Understanding that these factors may be at play when 
studying receptor function is essential when choosing the appropriate assay and concentration 
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of ligand. In order to tie WNT and Hh signals to cellular signalling events, gene reporter assays 
were developed to measure the transcription of target genes (Korinek et al., 1997; Sasaki et al., 
1997). These luciferase-based reporter assays were based on the co-activator -catenin binding 
to the transcription factor TCF to bind the c-Fos promoter or the transcription factor Gli binding 
to Gli responsive genes like the enhancer for hepatocyte nuclear factor-3 (HNF-3) for WNT 
and Hh signalling respectively. The time that it takes for luciferase to be expressed after ligand 
stimulation is considerably longer than the time it takes to measure the responses that take place 
upstream. Taking receptor activation as an example, conformational changes are quick and 
transient requiring higher concentrations of ligand than downstream readouts to achieve the 
maximum response. Using recombinant WNT or Hh proteins at saturating concentrations will 
activate effectors at all levels of the signalling cascade; however, the concentration of ligand 
contained in conditioned medium may be insufficient to detect responses upstream, but largely 
sufficient to measure downstream, end point readouts (including the caveat that quantification 
of agonist concentration in conditioned medium is intrinsically cumbersome). Given the 
ubiquitous expression of Class F receptors and redundancy among paralogues, the end point 
responses are more than likely a combination of receptor reserve and signal amplification. 
Building on this idea, it would be interesting to investigate how different concentrations of 
ligand and redundancy among FZD paralogues feeds into the channel capacity of systems 
dependent on WNT signalling (Keshelava et al., 2018). In view of this, ignoring the signalling 
events that take place immediately following ligand-receptor binding and the catalytic potential 
for proteins to amplify signals over several orders of magnitude is worrisome for the 
understanding of upstream signalling mechanisms and drug discovery. In the case of WNT 
signalling, there are certainly some open questions regarding the kinetic discord between 
WNT/-catenin signalling and -catenin-independent signalling. Are these pathways truly 
independent of one another or is there a justifiable kinetic component that integrates this all 
together (i.e. negative feedback loop or crosstalk)?  
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2 SPECIFIC AIMS 
The main objective of this thesis is to understand the mechanisms underlying Class F receptor 
activation. The specific aims are to: 
 Gain insight into FZD complex stoichiometry and dynamics 
 Study the GPCR nature of FZDs in the context of pharmacology 
 Define dynamic conformational changes involved in Class F activation 
 Aim to integrate findings between FZDs and heterotrimeric G proteins into cell 
models with physiological and pathophysiological relevance  
 Understand structural changes underlying agonist-induced or constitutive receptor 
activation 
 Develop assays that can be used to screen for FZD-targeting small molecules 
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3 MATERIALS AND METHODS 
All materials and methods that have been used to produce the results that make up this thesis 
(see Table 1) are described at length in the papers themselves. However, there are some 
methodological considerations that will be discussed herein. 
3.1 DECIPHERING WNT-FZD 
SELECTIVITY 
WNTs are ubiquitously expressed across cell 
types and there is no concrete method for 
quantifying the amount of protein expression of 
the individual paralogues. Not surprisingly, FZDs 
are also expressed in a ubiquitous manner and it 
is known that a certain degree of redundancy 
exists amongst them (Bhanot et al., 1999; Wang 
et al., 2006). This has slowed down efforts to nail 
down WNT-FZD selectivity and has pushed for 
the development of a number of tools in recent 
years. Initial efforts focused on finding cell types 
that expressed select FZDs or little to no FZDs at 
the mRNA level. This led to the use of mouse 
bone marrow derived 32D cells that expressed 
little to no FZD mRNA and were unresponsive in 
classical WNT signalling readouts without the 
introduction of exogenous FZD (Dijksterhuis et 
al., 2015). However, these cells were difficult to 
transfect and only a few stable lines could be 
generated. A more protein-centric approach 
utilized isolated anti-FZD Fabs that collectively 
became known as the “FZD profiler” – a flow cytometry-based method to discriminate the 
expression of FZD paralogues (Steinhart et al., 2017). With this knowledge in hand, one can 
attribute signalling responses to particular paralogues with greater certainty. During the same 
time, efforts were ongoing to multiplex CRISPR/Cas9-mediated gene editing in order to 
knockout all FZD paralogues. This resulted in two mutant HEK293 cell lines: FZD1,2,4,5,7,8-/- 
(Voloshanenko et al., 2017) and FZD1-10-/- (Eubelen et al., 2018) – the latter being completely 
depleted of FZDs. So far, no group has succeeded in knocking out all 19 WNT paralogues. 
Packaging cell lines like HEK293 cells have been the first choice for gene inactivation 
experiments due to their readiness to accept foreign DNA. In cell types that have a normal 
karyotype, the essentiality of the gene in question can result in a loss in viability.  
For Paper I, a number of CRISPR-based approaches were also used to study the role of 
endogenous FZD6 in MLE-12 cells. Firstly, wild-type Cas9 was directed to exon 3 of FZD6 
Method Paper 
AlphaScreen III 
BRET II, III 
Ca2+ mobilization II, III 
CD I 
Cell culture I, II, III 
Cell viability assay II 
Confocal microscopy I, II, III 
CRISPR/Cas9 I 
dcFRAP I, II 
DMR II 
FC(C)S I 
FRET II 
Immunoblotting I, II, III 
ITC I 
Molecular modeling I, II, III 
Mutagenesis I, III 
SEC I 
Transfection I, II, III 
Table 1. Methods used to produce the data 
presented in this thesis. 
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and clonal analysis was performed to screen for homozygous knockouts. For reasons unknown, 
only heterozygous lines were generated that had reduced FZD6 expression and were deficient 
in phosphorylation of ERK1/2 and their ability to proliferate. Another approach made use of 
the endonuclease-incapable dCas9 that was directed to the transcription start site (TSS) of 
FZD6. Although differences could be observed at the mRNA level, protein expression was not 
consistently different – possibly due to tight regulation of mRNA translation irrespective of 
CRISPR interference (unpublished data). The opposite effect was seen after CRISPR activation 
using dCas9-VP160 directed to the promoter of FZD6. An increase in mRNA levels of FZD6 
led to greater protein production resulting in more phosphorylation of ERK1/2.  
Because of the focus on FZD6 in Paper I, the physiological relevance of using a cell type that 
depends on FZD6 expression seemed logical. In retrospect, it may have been easier to use some 
of the aforementioned tools – had they existed at the time – to 1) confirm protein expression of 
all paralogues in MLE-12 cells or 2) use a packaging cell line depleted of all FZD paralogues 
and reintroduce FZD6, but with less physiological relevance. Moreover, the effects mediated 
by FZD6 in MLE-12 cells were not controlled for WNT-induced activation and therefore could 
be the result of constitutive activity. See 3.2 Inverse agonism, constitutive activity and 
method sensitivity for more information.  
3.2 INVERSE AGONISM, CONSTITUTIVE ACTIVITY AND METHOD 
SENSITIVITY 
The discovery of small molecules that target WNT secretion by inhibiting Porcupine (Liu et 
al., 2013; Proffitt et al., 2013) – the protein that acylates WNTs – enables one to create a 
biological system that is free of WNTs and this allows for measurements of constitutive activity 
in the presence of overexpressed FZD. Because inverse agonists that bind to FZDs have not 
yet been discovered, measuring the constitutive activity of endogenous FZDs is not currently 
possible.  
Nevertheless, small molecule inhibitors that prevent WNT secretion can allow us to study FZD 
function in an overexpression paradigm with the caveat that the ability to say with absolute 
certainty whether a receptor displays constitutive activity depends on the sensitivity of the 
method. A prime example of this is apparent from the results presented in Paper I and Paper 
III. In Paper I, it was concluded from semi-quantitative immunoblotting that in the absence of 
endogenous WNTs, overexpressed wild-type FZD6 did not display constitutive activity. In 
Paper III, the more sensitive and quantitative AlphaScreen assay was also used to measure 
constitutive activity of wild-type FZD6 – this time in comparison to another mutant – and 
despite there not being sufficient statistical power, there was a visible difference in the amount 
of activity compared to the control condition. In short, as the methodologies become more 
sensitive, we will gain greater insight into the action of drugs or the activity of proteins that 
were not previously measurable.  
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3.3 AFFINITY VS. PROXIMITY AND THE ROLE OF STOICHIOMETRY 
Receptor complex formation is an important area of research in WNT signalling where 
numerous co-receptors, scaffolding proteins and intracellular effectors have been implicated in 
a plethora of signalling pathways (Schulte and Wright, 2018). In order to piece together the 
building blocks that create functional receptor complexes, an understanding of protein complex 
stoichiometry is required – that is to say the relative amount of one protein to another.  
In Paper I and Paper II, dcFRAP was used to measure receptor-receptor interaction and 
receptor-effector interaction in combination with antibody-mediated and chemical crosslinking 
respectively. In both instances, an excess of the crosslinked protein was needed to ensure that 
if there was an interaction, then it would be detectable. To this end, an artificial transmembrane 
protein consisting of the two fluorophores used in the assay (mCherry and GFP) was 
constructed. This tool was aptly called a stoichiometer because it allowed for an approximation 
of the relative amount of one protein to the other (Petersen et al., 2017). Equating the relative 
fluorescence intensity of one fluorophore to the other ensured that dcFRAP experiments were 
comparable and strengthened our findings. Since dcFRAP experiments rely on the diffusion of 
unbleached, uncrosslinked proteins into an area where crosslinked proteins have been 
immobilized, we can conclude that if the uncrosslinked proteins are restricted in their 
movement, this is due to an affinity for the crosslinked proteins. By consequence, shifting 
stoichiometry in favour of the crosslinked population should result in a greater immobilization 
of the uncrosslinked population if there is indeed an interaction. The inclusion of appropriate 
positive or negative controls such as monomeric or dimeric reference proteins, membrane-
tethered fluorescent proteins or artificial single-pass transmembrane proteins fused with 
fluorescent proteins should support the data (Arthofer et al., 2016; Digby et al., 2006; Dorsch 
et al., 2009).  
Contrary to dcFRAP, RET-based approaches provide an indication about the proximity 
between two proteins (10 nm or 100 Å). Without proper controls and/or complementary 
techniques, conclusions about protein interaction cannot be determined by RET. Building on 
concepts derived from radioligand binding assays assuming 1:1 stoichiometry, the idea to 
titrate acceptor concentration in BRET experiments in an attempt to perform saturation analysis 
has led to conflicting reports regarding the absence or presence of a given interaction (e.g. 
receptor dimerization) (Lan et al., 2015; Mercier et al., 2002). Early seminal studies 
demonstrated that the amount of energy transfer between two interacting proteins depended on 
the stoichiometry between donor and acceptor rather than simply acceptor expression. In other 
words, energy transfer should increase irrespective of whether two proteins specifically interact 
with one another or collide randomly with one another; however, the nature of this increase 
will be linear rather than hyperbolic (Kenworthy and Edidin, 1998; Lan et al., 2015; Wan et 
al., 2018; Wolber and Hudson, 1979). If energy transfer is to be deemed specific, then it must 
also depend on donor concentration. It has become standard practice when performing 
saturation analysis in BRET experiments to plot energy transfer as a function of acceptor to 
donor. While the underlying assumption is that the amount of donor DNA has been kept 
constant, cellular machinery can favour expression of the acceptor at higher concentrations, 
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thereby reducing expression of the donor. This can transform data that would normally be linear 
into hyperbolic. Although this type of data transformation facilitates the pooling experimental 
replicates, it neglects the fact that protein expression does not always mirror DNA transfection. 
For that reason, controls should be carried out to confirm the presence or absence of a 
presupposed interaction (i.e. two known non-interacting proteins, mutated binding 
site/interface). RET can also be used to harness the random, non-specific interactions. This type 
of RET – known as bystander RET – relies on subcellular markers to ascertain where a protein 
of interest is localized (Lan et al., 2012). 
3.4 SPECIFIC ACTIVITY AND FZD PHARMACOLOGY 
Current methodologies allow for two main ways to stimulate cells/organoids with WNTs: 
conditioned medium and recombinant protein. WNTs are post-translationally modified through 
acylation and lipidation affecting trafficking and solubility (Janda et al., 2012; Langton et al., 
2016). While the WNT-conditioned medium produced from L-cells is cheaper and more stable 
under culture conditions, it is not pure nor do we have any idea what other co-factors or proteins 
may confound the response being measured. Therefore, it is not possible to perform accurate 
concentration-response experiments. Moreover, the concentration of WNT present in 
conditioned medium is much lower than commercially-available, purified, recombinant WNT. 
This is not a problem when measuring signal-amplified downstream readouts, but becomes an 
issue when higher concentrations are required to measure protein activation at the level of the 
receptor complex. Whereas conditioned-medium certainly has its place in many functional 
readouts (e.g. transcriptional readouts) as well as in the maintenance of stem cell/organoid 
cultures, it is not used in studies of FZD pharmacology. Protein biochemists and 
pharmacologists alike have struggled in purifying the WNT paralogues due to their high 
lipophilicity and susceptibility to protein degradation/inactivation. Nowadays, several WNTs 
are commercially available with or without carrier protein (e.g. bovine serum albumin). One of 
the drawbacks to using recombinant WNT is the variable specific activity between WNT 
paralogues. 
Based on previous experiments carried out on serum-deprived microglia cells and the sensitive 
nature of mitogen-activated protein kinase (MAPK) responses, WNTs without carrier were 
used in Paper I to measure the phosphorylation of ERK1/2. In contrast to this, information was 
collected from several recent publications (Dhamdhere et al., 2014; Mihara et al., 2016; Tüysüz 
et al., 2017) and in discussion with other GPCR pharmacologists, several measures were taken 
to produce the concentration-response curves in Paper II and III. Namely, recombinant WNT 
with carrier was maintained in assay buffer containing equimolar carrier protein. Serial 
dilutions of ligand were carried out in coated plastics to minimize protein adsorption. Where 
possible, experiments were performed using freshly reconstituted WNT that was maintained 
on ice until stimulation at room temperature. These methodological considerations ensured the 
reproducibility of these findings. More work is required to circumvent this problem in working 
with the endogenous FZD ligand or a switch must be made to small molecules that are easier 
to handle, less costly and more robust.  
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4 RESULTS AND DISCUSSION 
4.1 AGONIST-INDUCED DYNAMICS OF FZD DIMERS AND SIGNALLING 
The observation that DVL had a modulatory role on heterotrimeric G protein coupling to FZD6 
led us to hypothesize that a higher order complex was required to accommodate the binding of 
both DVL and G protein (Kilander et al., 2014). This hypothesis was consistent with the finding 
that other Class F members dimerize (Kaykas et al., 2004; Wang et al., 2013) and the steric 
requirement for DVL to contact ICL1-3, the H8 KTxxxW motif and the lipid headgroups 
(Gammons et al., 2016; Wong et al., 2000). The intracellular surface area required to 
accommodate both DVL and G protein does not appear to follow the same mechanism 
described by the recent discovery of a monomeric GPCR that can engage both G protein and 
β-arrestin simultaneously (Thomsen et al., 2016).  
In Paper I, we pursued this rationale and demonstrated via dcFRAP and FCCS that FZD6 
forms dimers – data that were supported by a SMO crystal structure (Wang et al., 2013). 
Mutational analysis and expression of dimer-interfering minigenes linked the dimer interface 
to TM4/5. Upon receptor activation, the -helical domain of the G subunit of the G protein 
is predicted to undergo a conformational switch that would sterically clash with a TM4/5 dimer 
(Cordomí et al., 2015). This was confirmed by dcFRAP and FCCS after stimulation with the 
FZD ligand WNT-5A, which led to the transient dissociation of FZD6 dimers. In order to study 
the physiological signalling output of FZD6, we turned to cells derived from the distal 
bronchiolar and alveolar epithelium of mouse lung epithelium – MLE-12 cells. The addition of 
recombinant WNT-5A to MLE-12 cells resulted in a time-dependent increase in ERK1/2 
phosphorylation that kinetically coincided with the dissociation/reassociation of FZD6 dimers. 
CRISPR/Cas9-mediated activation and inactivation of FZD6 in MLE-12 cells showed that 
ERK1/2 phosphorylation is regulated by FZD6 expression in the presence of endogenous 
WNTs. Given the G protein-mediated activation of ERK1/2, these findings merged well with 
previous data demonstrating that FZD6 was a Gi/q-coupled receptor (Kilander et al., 2014). In 
HEK293 cells treated with Porcupine inhibitor, expression of the FZD6 dimer mutant continued 
to signal to ERK1/2 in a ligand-independent manner contrary to wild-type FZD6.  
Further investigation is required to understand how the FZD6 dimer mutant is capable of 
signalling to ERK1/2 while not being able to preassociate with Gi1. One possibility is that 
FZD6 monomers are incapable of forming stable complexes with heterotrimeric G proteins and 
interact via collision coupling. Further experiments are required to confirm this hypothesis, but 
this could be tested in a RET-based set-up using donor-tagged G and acceptor-tagged G 
(Andressen et al., 2018). In sum, this suggests that while FZD6 monomers are sufficient to 
initiate signalling, dimers represent the inactive, ligand-responsive form of FZD6 as 
summarized in Fig. 6. These findings are supported by the fact that all active Class A and B 
GPCR structures to date have been monomeric (Gurevich and Gurevich, 2018). 
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4.2 FZDs UNDERGO CONFORMATIONAL CHANGES CONSISTENT WITH 
GPCR ACTIVATION 
The structural changes that coincide with GPCR activation were largely elucidated by the 
crystal structure of the fully active β2 adrenergic receptor in complex with heterotrimeric Gs. 
Compared to inactive structures, the active structure exhibited a large outward movement of 
TM6 (Rasmussen et al., 2011a). In recent years, a number of Class A/B GPCR structures have 
been solved in complex with heterotrimeric G proteins or G protein surrogates (e.g. mini G 
proteins or nanobodies) (Carpenter et al., 2016; García-Nafría et al., 2018; Liang et al., 2018b; 
Rasmussen et al., 2011b; Tsai et al., 2018; Zhang et al., 2017). Conflicting structural 
information and controversy within the Class F has befuddled our understanding of how these 
receptors transduce signalling. Similar to FZDs, there has also been a resistance to accept SMO 
as a GPCR due to its strong link to Hedgehog signalling (Arensdorf et al., 2016). Drawing 
parallels with prototypical GPCRs, it was suggested that cholesterol and cyclopamine bind the 
CRD to activate SMO by inducing a conformational change in TM6 in the absence of G protein 
(Huang et al., 2016); although, this could be explained by the insertion of a crystallization 
scaffold into IL3 (Lefkowitz et al., 2008). Contrary to this, molecular dynamics simulations 
were run on the inactive structure of ΔCRD-FZD4 in a ligand-free state and TM6 remained 
closely packed in the transmembrane domain (Yang et al., 2018). While GPCR structures 
represent snapshots of a particular conformational state, molecular dynamics simulations 
provide information about the propensity of a GPCR to sample different conformations and the 
lifetimes of those conformations (Dror et al., 2011).  
These inconsistencies within the Class F necessitate further studies in order to elucidate the 
structural changes resulting upon ligand binding. In Paper II, we used a fluorescein arsenic 
hairpin binder (FlAsH)-based FRET approach to monitor receptor activation of FZD5. Based 
Fig. 6. Agonist-dependent dynamics of FZD6 dimerization. FZD6 dimerizes via TM4/5 and after binding of 
WNT-5A, it dissociates to produce active signalling monomers that will reassociate upon signal termination. 
WNT-5A
signaling
GPCR dimer
agonist
transient dimer
dissociation
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on knowledge of the outward movement of TM6 upon receptor activation and studies using a 
similar approach on Class A GPCRs (Hoffmann et al., 2005; Maier-Peuschel et al., 2010; 
Ziegler et al., 2011), we cloned the FlAsH binding motif into the third intracellular loop of 
FZD5 and fused cyan fluorescent protein (CFP) with its C-terminus. The addition of 
recombinant WNT-5A led to a decrease in FRET between CFP and FlAsH suggestive of a 
conformational change not unlike prototypical GPCRs (Fig. 7). Due to the technical difficulties 
in radioactively labelling WNTs, this approach represents a major development in assessing 
WNT-FZD specificity – the results obtained are equivalent to a ligand binding assay. Future 
studies will certainly exploit this tool to unravel the specific interactions between the 19 WNTs 
and 10 FZDs with the caveat that their potencies and efficacies cannot be compared without an 
idea of the specific activity of purified ligands (see 3.4 Specific activity and FZD 
pharmacology). 
 
4.3 PHARMACOLOGICAL ASSESSMENT OF FZD FUNCTION 
FZDs are poorly understood pharmacologically and this is in large part due to the chemical 
nature of WNTs (see 3.4 Specific activity and FZD pharmacology) and the lack of small 
molecule drugs acting on these receptors (Schulte and Wright, 2018). In Paper II, we 
employed RET-based biosensors to monitor receptor activation and map downstream 
signalling by generating concentration-response relationships. Although these biosensors are 
highly engineered to maximize the signal-to-noise ratio, they are robust and reliable tools for 
reading out GPCR activity (Galés et al., 2006; Saulière et al., 2012). The contribution of 
endogenous G proteins to the observed responses requires some discussion. Using 
pharmacological inhibitors of Gαq/11/14 and phenotypic rescue of Gαq/11KO cells, we 
demonstrated that FZD5 signals through Gαq after application of recombinant WNT-5A using 
BRET sensors that detect endogenous phospholipase C (PLC) and PKC activity as well as 
whole-cell activation measured by DMR (Fig. 8). The observation that this activity depends on 
expression of FZD5 supports the intrinsic ability of this receptor to functionally interact with 
Fig. 7. FZD5 undergoes a conformational upon agonist addition. (A) Stimulation of the FZD5-FRET sensor 
with a maximum concentration of recombinant WNT-5A leads to a decrease in RET between the donor-tagged 
C terminal tail and the acceptor-tagged IL3. (B) Concentration-response experiments with the FZD5-FRET 
sensor support the idea that we can measure both ligand binding and conformational changes. 
94
96
98
100
102
104
1 2 3 4
log[WNT-5A], ng/mL
FR
ET
 ra
tio
 (%
 o
f v
eh
ic
le
)
V5-FZD5-FlAsH436-CFP (microplate)
-
BA
V5-FZD5-FlAsH436-CFP (single cell)
time (s)
no
rm
al
iz
ed
 F
R
ET
 ra
tio
0 10 20 30 40 50 60 70 80 90
0.94
0.95
0.96
0.97
0.98
0.99
1.00
1.01
1.02
1.03
WNT-5A
 24 
heterotrimeric G proteins in living cells. However, the contribution of G proteins to the 
conformational changes observed in the FZD5 FRET probe and other RET-based GPCR probes 
is less clear. Everything from no involvement to a direct involvement to extended kinetics of 
the agonist-induced response have been observed using prototypical GPCRs; thus, 
complicating interpretation of RET changes beyond ligand binding (Kauk and Hoffmann, 
2018). Taken all together, these findings highlight the conformational diversity of GPCRs 
resulting from ambiguous cellular complexities like stoichiometry and equilibria that still 
require careful dissection – especially in the case of FZD5 for which this has not yet been 
studied – in order to ascertain what drives a particular conformation and how that relates to 
receptor output in terms of signalling. Nevertheless, the concentration-response data presented 
in Paper II represents the first time – to our knowledge – that comparative pharmacology has 
been used in the context of WNT/FZD signalling in order to link ternary complex formation to 
downstream readouts. 
4.4 IDENTIFICATION OF A MOLECULAR SWITCH IN CLASS F RECEPTORS  
The absence of conserved motifs pertinent to Class A receptor activation has long been an 
argument against the GPCR nature of Class F receptors (Angers and Moon, 2009). This is in 
stark contrast to Class B/C receptors, which have evolved different motifs to arrive at a 
functionally equivalent signalling outcome – GEF activity. Disruption of the ionic lock or polar 
network in Class A and B receptors respectively is an integral step in receptor activation  
(Ballesteros et al., 2001; Liang et al., 2018b). An equivalent motif was recently identified in 
cholesterol- and cyclopamine-bound SMO structures without any insight into its functional 
relevance (Huang et al., 2016). Given the relevance of FZDs and SMO in cancer, we 
hypothesized that mutated residues important in Class F receptor activation would have a 
higher frequency in cancer patients compared to the general population (Paper III). Based on 
this rationale, we identified an arginine/lysine in position 32 on TM6 that formed hydrogen 
Fig. 8. FZD5 utilizes endogenous Gq to activate downstream effectors and mediate whole-cell changes. 
(A) HEK293 cells expressing the PKC biosensor and FZD5 were stimulated with WNT-5A in the presence or 
absence of inhibitors of Gα q or PKC proving that PKC is both active and downstream of Gαq/11. A similar 
setup was used in Gαq/11KO cells to confirm that the PKC response was exclusively dependent on Gαq. (B) 
DMR experiments on HEK293 cells that expressed or did not express FZD5 revealed that cells responded to 
WNT-5A in a FZD5- and Gαq-dependent manner.   
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bonds with the oxygen atoms of the TM7 helical backbone and -cation interactions with the 
side chain of the conserved tryptophan in position 55 of TM7 – the same residues identified in 
the aforementioned study. In line with the genomic analysis of these patient datasets, structural 
analysis and molecular dynamics simulations confirmed the propensity of the hydrophobic 
alanine substitution in position 6.32 to produce a more open conformation. The outward 
movement of TM6 observed in the ligand-bound SMO structures and the loss in FRET 
observed upon WNT addition to cells expressing the FZD5 sensor in Paper II collectively point 
to a molecular switch in Class F receptors that confers a conformational change in an agonist-
bound state. Focusing on FZD6, it became clear that the R416A mutant conveyed a higher 
ligand-induced activity and greater constitutive activity compared to the wild-type receptor in 
terms of calcium mobilization and phosphorylation of ERK1/2 respectively. Whereas there was 
a clear increase in the ability of FZD6 to signal through heterotrimeric G proteins upon 
disruption of the molecular switch, the receptor was no longer capable of interacting with or 
inducing the phosphorylation signature on DVL that is characteristic of WNT pathway 
activation. In order to address this inherent bias, we performed concentration-response 
experiments with conformational sensors of the active GPCR state known as mini G (mG) 
proteins. Originally engineered to stabilize the active state of several GPCRs for the purpose 
of crystallization, they have recently been repurposed as cytosolically expressed BRET sensors 
that translocate to the membrane upon receptor activation (Carpenter et al., 2016; García-Nafría 
et al., 2018; Tsai et al., 2018; Wan et al., 2018). The shift in agonist potency observed for all 
representatives of the homology clusters of the Class F in the presence of mG protein follows 
the ternary complex model for GPCRs whereby the G protein can allosterically affect the 
receptor in such a way that confers increased affinity for the agonist (De Lean et al., 1980; 
Rasmussen et al., 2011a) (Fig. 9). 
One of the caveats to this particular BRET-based setup is the dependency on direct RET 
between the luciferase-tagged receptor and the Venus-tagged mG protein. Consistent with the 
division of FZDs and SMO into their respective homology clusters, the length of the C-tail 
varies considerably and by consequence, the distance between the luciferase and the Venus as 
well as the dipole orientation can affect the RET efficiency and ultimately the apparent efficacy 
of the interaction. For this reason, it is impossible to compare different Class F members with 
each other and with other GPCRs in their ability to couple to mG proteins in this experimental 
paradigm. One possibility to circumvent this problem would be to use BRET sensors of G 
protein activation where the G subunit acts as a donor for the acceptor G subunit. This 
approach was successfully used for FZD5 in Paper II where the dynamic window displayed a 
marked difference compared to the response observed in the mG protein setup. In short, while 
we can readily detect a difference in agonist potency between wild-type and mutant receptors, 
other assays would be necessary to measure G protein coupling in the absence of an agonist-
induced increase in BRET (e.g. wild-type FZD7).  
The choice of ligand should also be considered when probing for the active state of a GPCR. 
In Paper III, we limited the study to WNT-5A when looking at FZDs and Smoothened agonist 
(SAG) when looking at SMO. SAG is an obvious first choice since it is a synthetic small 
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molecule ligand that has been co-crystallized with SMO (Wang et al., 2014). However, the 
interaction profile between the 19 WNTs and 10 FZDs is less clear and largely based on binding 
experiments with recombinant CRD (Dijksterhuis et al., 2015). Therefore, we cannot say with 
certainty whether WNT-5A was a partial agonist or a full agonist in mG protein recruitment 
for the selected FZDs in the study.  
 
4.5 USING SMO AS A BASIS FOR TARGETING FZDs 
PHARMACOLOGICALLY 
Our structural insight into the activation mechanisms of Class F receptors remains limited 
despite advances in obtaining atomic resolution structures. Multidomain, ΔCRD and 
recombinant CRD structures in complex with diverse ligands have been solved; however, there 
is no indication how a two-component complex leads to receptor activity. SMO ligands have 
been crystallized bound to the CRD and the more traditional GPCR binding pocket in the TMD. 
Current dogma based on the FZD8-CRD/WNT-8 crystal structure places the WNT binding site 
on the CRD (Janda et al., 2012). Norrin and Clostridium difficile toxin B have also been shown 
to interact with the CRD underlining its importance in the FZD binding mode. Conclusions 
drawn from the recent crystal structure of apo-Δ   CRD-FZD4 have reinforced the idea that FZDs 
behave differently from prototypical GPCRs. FZD4 has a narrow, hydrophilic pocket in the 
transmembrane domain and a short TM6 that is tightly packed with the rest of the helical bundle 
(Yang et al., 2018). However, these findings fall short in explaining our findings in Paper II 
and Paper III. As exemplified by FZD5 in Paper II, the differences in FRET upon agonist 
binding reflect conformational changes consistent with prototypical GPCR activation and 
inconsistent with dynamic kinks in TM7. Along the same line, all representative FZDs where 
the molecular switch had been mutated in Paper III displayed a shift in agonist potency in the 
Fig. 9. Class F receptor activation. Different activation states of Class F receptors in the presence and absence 
of receptor-activating ligands, mG protein or molecular switch mutation. 
Receptor activation level
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presence of mG protein 
reflecting changes in the agonist 
binding site that cannot 
exclusively be explained by 
WNT binding to the CRD. In 
other words, the thumb and 
index finger of WNT grasping 
the CRD cannot explain 
changes in the transmembrane 
bundle that would result in the 
observed conformational 
changes in either TM6 (as 
described for prototypical 
GPCRs) or TM7 (as proposed 
for FZD4). One possibility that 
requires experimental validation could be an analogous multi-step binding mode as described 
for Class B receptors (Schwartz and Frimurer, 2017). In the absence of agonist-bound full-
length FZD structure, evidence is mounting that FZDs can be targeted via the traditional 
heptahelical ligand binding pocket. In Paper III, we further characterized the effect of small 
molecule SMO ligands that exert their effects on the 7TM core on the SMO Arg6.32 mutant. 
Treatment of cells expressing the SMO Arg6.32 mutant with cyclopamine-KAAD reversed the 
potency of SAG to values comparable to wild-type SMO (Fig. 10). Given the conserved 
activation mechanism in Class F and the finding that intracellular transducer binding can 
allosterically affect agonist affinity, this provides a proof-of-principle that FZDs can be 
drugged in a similar way to SMO – opening the door to new treatments targeting WNT/FZD 
signalling in disease.  
   
 
Fig. 10. Agonist potency shift of SMO R455A6.32 can be reversed. 
SAG-induced SMO R455A6.32 recruitment of mGsi is sensitive to 
inverse agonist suggesting that a similar small molecule approach 
could be used to target FZDs of equivalent mutations in disease. 
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5 CONCLUSION AND FUTURE PERSPECTIVES 
The processes that guide the zygote to transition into a developing embryo are governed in 
large part by WNT and Hh signalling. Throughout gestation and into adult life, these signalling 
pathways are tightly regulated to ensure the physiological well-being of an individual. This 
molecular regulation is complex, orchestrated and fine-tuned during development beginning at 
the subcellular level to drive cell fate determination and organogenesis. Despite being 
conserved from worms to mammals, the complexity has increased over millions of years of 
evolution. In humans, there is a considerable disease burden due to misregulation of these 
pathways at the genetic and molecular levels. For this reason, there is a social demand for 
therapies that will increase life expectancy and improve its quality.  
More than 30 years of WNT and Hh signalling research has answered many pertinent 
questions, but left us with several times as many more. One of the key unanswered questions 
revolves around the structural changes that occur in FZDs and SMO to induce pathway 
activation. The papers presented in this thesis aim to understand the dynamic, structural 
changes that reflect the switch from an inactive receptor to an active and transducer-bound 
Class F receptor. Their findings are highlighted here: 
Paper I 
 FZD6 – one of 11 Class F paralogues – forms dimers in living cells  
 FZD6 dimerization is sensitive to WNT stimulation 
 The dimer interface of FZD6 is formed by TM4/5  
 FZD6 dimers are the inactive, ligand recognizing species 
 Ligand-induced production of monomers results in receptor activity  
Paper II 
 WNT-5A stimulation of FZD5 results in a conformational change  
 FZD5 forms an inactive state complex with Gq  
 WNT-5A stimulation of FZD5 leads to the activation of Gq, production of DAG, 
mobilization of intracellular Ca2+, activation of PKC and whole-cell activation 
 Pancreatic cancer cells – that functionally rely on FZD5 for proliferation – are sensitive 
to Gq inhibition 
Paper III 
 R6.32 is the most prevalently mutated residue in cancer compared to population-level 
variation 
 Network of residues between TM6/7 constitute a molecular switch 
 Disruption of the molecular switch leads to higher agonist-induced and constitutive 
activity of FZD6  
 Analysis of the ability of FZD5 and FZD6 to signal through DVL reveals that 
mutagenesis of the molecular switch introduces receptor bias that feeds into pathway 
selectivity 
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 Conformational sensors of the active G protein-bound receptor state confirm that Class 
F receptor mutants are biased towards G protein signalling conferring higher agonist 
potency – indicative of a high affinity ternary complex 
 Inverse agonist treatment of mutant SMO demonstrates the reversibility of this 
phenotype and the applicability of similar drug design to FZDs 
The complexity of these signalling pathways has been a major roadblock for drug discovery 
efforts. Because WNT and Hh signalling are integral to development and adult tissue 
homeostasis, the issue of safety in the context of treatment has become a central concern (Kahn, 
2014). To reiterate, the aim of this thesis is to better understand Class F receptor activation with 
the hope that we can translate mechanistic findings to the clinics. However, these findings are 
limited to basic pharmacology and a subset of human tumours. For example, there is no logic 
to targeting WNT receptors in the treatment of APC mutant gastro-intestinal tumours due to an 
etiology that is receptor-independent (Minde et al., 2011). With that in mind, multiple points 
of intervention are possible and under investigation in the treatment of diseases with overactive 
WNT/Hh signalling at the cell surface. A prime example comes from ring finger protein 43 
(RNF43)-mutant pancreatic adenocarcinomas for which hypothetical points of intervention 
include Porcupine (PORCN), GPR177/Wntless, WNTs, FZDs which cannot be ubiquitinated 
by RNF43 and Gq.  
Antibodies that target the FZD CRD and chimeric CRD-Fragment crystallizable region (Fc) 
fusions have garnered some attention for their progression into clinical trials for the treatment 
of various cancers. However, vantictumab and ipafricept were both discontinued at the end of 
2017 begging the question whether antibody-based antagonism of WNT signalling to inhibit 
protein-protein interactions (PPIs) makes sense from a strategical standpoint. Studies based on 
the crystal structure of WNT-8 in complex with the FZD8 CRD have driven home the message 
that blocking the CRD will prevent WNT binding. What these studies have failed to consider 
is evidence of a multi-step binding mode in Class B receptors, a pharmacophore in the 7TM 
bundle of the Class F member SMO and evidence that we cannot achieve sufficient biological 
selectivity to target specific FZD paralogues. Nevertheless, from a development perspective, 
antibodies are advantageously more successful; they have a longer half-life in vivo and higher 
affinity and potency through specific selectivity – of which the latter is thus far unachievable 
among FZD CRDs. On the downside, they are more expensive, cannot penetrate cells and as 
foreign proteins, they are intrinsically immunogenic (Imai and Takaoka, 2006). Currently, 
several camelid-based antibodies called nanobodies have worked their way into clinical trials. 
Nanobodies are single domain fragments that maintain all of the advantages of conventional 
antibodies while boasting the ability to distinguish protein conformations and access cavities 
or clefts that larger antibodies would otherwise not be able to target (Steyaert and Kobilka, 
2011).  
Alternative molecular targeting strategies are already in place for SMO as evidenced by the 
inhibitor vismodegib – a small molecule inhibitor that binds the 7TM bundle and is currently 
being used to treat basal cell carcinoma. Contrary to antibodies, small molecules are less 
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expensive, easier to administer and have the potential to penetrate cells. Small molecules are 
notoriously less specific and there is the risk for pharmacokinetic variability affecting 
bioavailability across individuals (Imai and Takaoka, 2006). In spite of this, small molecule 
targeting of SMO has been successful resulting in the development of both agonists and inverse 
agonists that bind SMO in a traditional GPCR manner.  
From an inactive, tightly packed Class F transmembrane structure reinforced by receptor 
dimerization to disruption of a molecular switch in helices TM6/7 that leads to the outward 
movement of TM6 allowing for monomeric receptor engagement and activation of 
heterotrimeric G proteins, this thesis details the molecular events that entail Class F receptor 
activation. FZDs and SMO are dynamic proteins that respond bidirectionally to stimuli through 
conformational changes in their protein structure. The fundamental understanding that GPCRs 
are molecular machines whose activities are distinguished by their conformations has not been 
empirically applied to FZDs nor SMO. The work detailed in this thesis provides the foundation 
for future studies into Class F receptor activation that will dig deeper into the conformational 
landscapes of the receptors implicated in WNT and Hh signalling. More specifically, the 
methods used in this thesis to measure FZD and SMO activity begin to illuminate what was 
previously referred to as the “black box” of WNT and Hh signalling (Schulte, 2015).  
This raises the following question: how can these findings and methods be used moving 
forward to screen for new drugs that can be used to treat diseases of aberrant WNT or Hh 
signalling?  
The answer is multifactorial, but lies in 1) the scalability of the method – of which several in 
this thesis can be used in medium- to high-throughput screening, 2) an understanding of the 
target cell physiology and 3) a strategy to achieve paralogue selectivity and pathway specificity.  
RET-based biosensors and label-free approaches like DMR in combination with the recently 
described FZD1-10-/- mutant HEK293 cells (Eubelen et al., 2018) provide a logical starting point 
for systematically analyzing FZD paralogues. Although these cells do not adequately mimic 
the physiological context where the receptors are normally expressed, they are a practical 
system for characterizing FZD activation. Subsequent efforts will surely focus on 
contextualizing the effect of the drug in physiological relevant cell and model systems where 
intracellular effectors, trafficking properties and overall protein composition may differ.  
The issue of subtype selectivity is not new to the GPCR superfamily. Muscarinic receptors – 
of which there are five paralogues M1-M5 – all bind and mediate acetylcholine signalling. This 
has led to the development of dualsteric ligands that bind both orthosteric and allosteric sites 
to achieve subtype selectivity (Antony et al., 2009). While this is obviously not an equivalent 
analogy given that 19 WNTs exist for 10 FZDs, it offers some idea for how antagonists or 
inverse agonists may be designed to eliminate poor paralogue selectivity. 
In conclusion, FZDs and SMO are GPCRs that dynamically and functionally respond to stimuli 
to mediate the activation of intracellular transducers including heterotrimeric G proteins. More 
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work needs to be done to address the drawbacks and failures associated with current drug 
treatments targeting diseases of WNT signalling. Integration of the kinetic responses that are 
fast and transient at the plasma membrane in a physiologically relevant manner with the 
downstream signalling cascades that lead to transcriptional regulation will facilitate these 
efforts and hopefully bring relief to those afflicted by disease.  
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6 SAMMANFATTNING 
Vår genetiska uppsättning består av tusentals gener som kodar för de proteiner som är 
involverade i alla aspekter av våra cellfunktioner. Proteiner är molekylära maskiner som 
dynamiskt och strukturellt svarar på stimuli. Våra celler besitter förmågan att känna av sin 
omgivning och att reagera följaktligen med hjälp av speciella proteiner kallas receptorer. Dessa 
ligger inbäddade i det cellulära membranet och binder till extracellulära molekyler kända som 
ligander. Receptorernas karaktäristiska förmåga att specifikt interagera med och påverka 
strukturella ändringar hos partnerproteiner utgör basen för signalkaskaden som reglerar 
cellulära processer. Vid sjukdomstillstånd kan genetiska mutationer resultera i ändringar i 
proteinstruktur som kan påverka receptorernas tertiära och kvartära struktur i 
proteinkomplexet. Detta kan resultera i drastiska effekter på proteinfunktion och så småningom 
cellens förbestämda öde.  
Användningen av animaliskt och växtbaserade produkter inom den moderna medicinen har lett 
till utvecklingen av farmakologin – läran om hur levande organismer påverkas av läkemedel. 
Tekniker för märkning av receptorer och molekylär kloning har gjort det möjligt att fastställa 
att flera av dessa molekyler agerar på receptorfamiljen vid namn G proteinkopplade receptorer 
(GPCRer). Vår kunskap gällande receptorernas strukturella ändringar vid ligandinbinding har 
bidragit till utvecklingen av nya läkemedel med bättre specificitet och färre biverkningar.  
Medan vår kunskap relaterad till prototypiska GPCRer som adenosinreceptorer och 
opioidreceptorer har ökat de senaste åren har kunskapen kring deras avlägsna kusiner, kända 
som Frizzleds (FZDs) och Smoothened (SMO), dock lämnats utan möjligheter för utvärdering 
av deras GPCR egenskaper. FZDs interagerar med lipoglykoproteiner tillhörande WNT 
familjen medan SMO regleras indirekt av Hedgehog (Hh) för att samordna viktiga processer 
under den embryonala utvecklingen och homeostasen. Fel i WNT/FZD och Hh signaleringen 
leder till patogena tillstånd för vilka det oftast finns begränsade möjligheter för behandling. 
Med hänsyn till WNT signalering beror bristen på effektiva läkemedel som riktar sig mot FZDs 
främst på kunskapsbrist orsakad av den aktuella dogman som framhäver bildandet av 
proteinkomplex före strukturella ändringar involverade i proteinaktivering.     
Upptäckterna sammanställda i artiklarna I till III bistår med strukturella insikter i de 
mekanismer som ligger till grund för FZD/SMO aktivering. En kombination av genomiska, 
biofysiska samt biokemiska tillvägagångssätt har använts för att avslöja detaljer kring bildandet 
av FZD/SMO komplex och den strukturdynamik som uppstår då WNT binder och initierar full 
receptoraktivitet och nedströms signalering. Detta har betydelse för utveckling av effektiv 
behandling vid sjukdomstillstånd där FZDs och SMO kan användas som målmolekyler. 
Ytterligare karaktärisering av dessa receptorers konformationslandskap kommer att underlätta 
framtida försök för läkemedelsutveckling.
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